<DOC>
	<DOCNO>NCT00946114</DOCNO>
	<brief_summary>The purpose study provide sildenafil therapy eligible adult patient pulmonary arterial hypertension ( PAH ) patient complete A1481142 study treatment PAH Poland . Only safety tolerability data collect patient .</brief_summary>
	<brief_title>To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension For 112 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Subjects age 18 follow condition : Idiopathic pulmonary arterial hypertension . PAH associate connective tissue disease ( CTD ) . PAH surgical repair , least 5yrs previously , atrial septal defect ( ASD ) , ventricular septal defect ( VSD ) patent ductus arteriosis ( PDA ) aortapulmonary window . 2 . Subjects mean pulmonary artery pressure ( mPAP ) &gt; 25mmHg pulmonary artery wedge pressure ( PAWP ) &lt; 15mmHg rest , assess via right heart catheterization . 3 . Subjects whose baseline 6min walk test distance &gt; 100m &lt; 450m . 1 . PAH secondary etiology specify inclusion criterion . 2 . Subjects congenital heart disease ( specify inclusion criterion ) , PAH due thromboembolism , HIV , chronic obstructive airway disease , congestive heart failure . 3 . Subjects whose 6Minute Walk test might limit condition PAH , associate dyspnea fatigue .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>